• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

Recent Advances in the Study of 2-Nitronicotinamide (CAS: 60780-22-5) and Its Applications in Chemical Biology and Medicine

2-Nitronicotinamide (CAS: 60780-22-5) has emerged as a compound of significant interest in the fields of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have focused on its role as a precursor in the synthesis of bioactive molecules and its interactions with various biological targets. This research brief aims to summarize the latest findings regarding the synthesis, mechanism of action, and potential applications of 2-Nitronicotinamide in drug discovery and development.

One of the key areas of research has been the optimization of synthetic routes for 2-Nitronicotinamide. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an improved synthetic protocol that enhances yield and purity, making it more feasible for large-scale production. The study highlighted the use of catalytic hydrogenation and nitration techniques, which significantly reduced the formation of by-products. These advancements are critical for ensuring the compound's availability for further pharmacological evaluations.

In terms of biological activity, recent investigations have explored the compound's potential as an inhibitor of nicotinamide adenine dinucleotide (NAD)-dependent enzymes. A 2024 study in Chemical Biology & Drug Design reported that 2-Nitronicotinamide exhibits selective inhibition against certain NAD-dependent dehydrogenases, suggesting its utility in targeting metabolic pathways in cancer cells. The study utilized molecular docking and kinetic assays to elucidate the binding interactions, providing a foundation for the design of more potent derivatives.

Another promising avenue of research involves the application of 2-Nitronicotinamide in antimicrobial therapies. A preprint article from BioRxiv (2024) described its efficacy against drug-resistant bacterial strains, particularly in combination with existing antibiotics. The study proposed that the nitro group in 2-Nitronicotinamide enhances reactive oxygen species (ROS) production, leading to bacterial cell death. This finding opens new possibilities for addressing the global challenge of antibiotic resistance.

Despite these advancements, challenges remain in the clinical translation of 2-Nitronicotinamide. Issues such as bioavailability, toxicity, and off-target effects need to be addressed through further preclinical studies. A recent review in Expert Opinion on Drug Discovery (2024) emphasized the importance of structure-activity relationship (SAR) studies to optimize the compound's pharmacological profile while minimizing adverse effects.

In conclusion, 2-Nitronicotinamide (CAS: 60780-22-5) represents a versatile scaffold with significant potential in drug discovery and chemical biology. Ongoing research continues to uncover its mechanisms of action and therapeutic applications, paving the way for future innovations. Collaborative efforts between chemists, biologists, and clinicians will be essential to fully realize its promise in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)